Devices › Reagents, 2019-novel coronavirus nucleic acid
Device brand name · Real time rt-pcr assay for the ivd qualitative detection of sars-cov-2 viral rna
Simplexa Covid-19 Direct Assay: medical device reports filed with FDA
234 reports name it, 2021–2025. Product code QJR.
- 234
- device reports naming the brand
- 0% of all MAUDE reports · about 45 a year
- 0
- reports, 12 months to August 2026
- 5 in the 12 months before
- 100%
- classified as malfunction
- 98.4% across the product code
- 0%
- classified as death, as reported
- 0 reports · not verified by FDA
FDA's MAUDE database holds 234 reports that name the brand "Simplexa Covid-19 Direct Assay" (real time rt-pcr assay for the ivd qualitative detection of sars-cov-2 viral rna), received between May 2021 and April 2025. Spellings of one product vary from report to report.
0 reports arrived in the 12 months to August 2026, against 5 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (100%); across all reagents, 2019-novel coronavirus nucleic acid reports (product code QJR) death is recorded in 0% and malfunction in 98.4%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are false positive result (65%), false negative result (31.2%) and leak/splash (1.3%). The patient problems coded most often are appropriate clinical signs, symptoms and conditions term/code not available and viral infection. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 20,139 reports carrying product code QJR. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| False positive result | 152 | 65% | 66.6% |
| False negative result | 73 | 31.2% | 13.9% |
| Leak/splashthe device leaked | 3 | 1.3% | 0% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Appropriate clinical signs, symptoms and conditions term/code not available | 15 | 6.4% |
| Viral infectiona viral infection | 3 | 1.3% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Simplexa Covid-19 Direct Assay | Product code QJR | All MAUDE reports |
|---|---|---|---|
| Reports | 234 | 20,139 | 26,136,888 |
| Share of that pool | — | 1.2% | 0% |
| Classified as death, per 1,000 reports | 0 | 0 | 9 |
| Classified as injury | 0% | 1.5% | 36.2% |
| Classified as malfunction | 100% | 98.4% | 62.3% |
| Filed by the manufacturer | 100% | 98.5% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code QJR
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Id Now Covid-19 Assay | 3,418 | 0 | 0% |
| Cobas Sars-Cov-2 & Influenza A/B Test For Use On The Cobas Liat System | 2,026 | 0 | 0% |
| Cue Covid-19 Test For Home And Over The Counter Otc Use | 1,823 | 0 | 0% |
| Id Now Covid-19 | 1,134 | 0 | 0.4% |
| Cobas Sars-Cov-2 Test | 1,086 | 0 | 0% |
| Check-It | 930 | 0 | 0% |
| Aptima Sars-Cov-2 Assay | 726 | 0 | 0% |
| Alinity M Resp-4-Plex Amplification Reagent Kit | 630 | 0 | 0% |
| ID NOW COVID-19 2.0 Test KIT 24T JAPAN | 704 | 37 | 0% |
| Alinity M Sars-Cov-2 Amplification Reagent Kit | 535 | 0 | 0% |
| Id Now Covid 19 Assay | 523 | 0 | 0% |
| Id Now Covid-19 2 0 Test Kit 24t Ous | 489 | 0 | 0% |
| Lyra Direct Sars-Cov-2 Assay | 415 | 0 | 0% |
| Alinity M Resp-4-Plex Amp Kit | 409 | 69 | 0% |
| Accula Sars Cov-2 Test | 391 | 0 | 0% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Simplexa Covid-19 Direct Assay reports
How many FDA reports name Simplexa Covid-19 Direct Assay?
234 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.
What kinds of events are reported?
malfunction (100%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
false positive result (65%), false negative result (31.2%) and leak/splash (1.3%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Simplexa Covid-19 Direct Assay was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.